- Home
- FUBO vs RNA Comparison
FUBO vs RNA Comparison
Compare FUBO & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FUBO | RNA |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.1M | 222.5M |
| IPO Year | 2011 | 2025 |
Fundamental Metrics
Financial Performance| Metric | FUBO | RNA |
|---|---|---|
| Price | $11.65 | $10.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 20 |
| Target Price | $20.33 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 1.3M | 238.7K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,271,000.00 | N/A |
| Revenue This Year | $44.64 | $88.12 |
| Revenue Next Year | $5.62 | $18.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10317.07 | N/A |
| 52 Week Low | $1.02 | $10.34 |
| 52 Week High | $14.54 | $73.06 |
Technical Indicators
Market Signals| Indicator | FUBO | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 30.76 |
| Support Level | $8.49 | N/A |
| Resistance Level | $11.68 | $14.30 |
| Average True Range (ATR) | 0.70 | 0.76 |
| MACD | 0.05 | -0.40 |
| Stochastic Oscillator | 55.07 | 2.06 |
Price Performance
Historical ComparisonAbout FUBO fuboTV Inc.
FuboTV Inc is a sports-first, Pay TV replacement product offering subscribers access to tens of thousands of live sporting events annually, alongside news and entertainment content, both live and on demand. Its platform is designed to empower customers to seamlessly access content through streaming devices and on Smart TVs, mobile phones, tablets, and computers. The company offers subscribers a live TV streaming service with the option to purchase incremental features, including additional content or enhanced functionality suited to their preferences. Its subscription packages (including Fubo Essential, Pro, Elite, and others) boast a broad mix of top Nielsen-ranked channels across sports, news, and entertainment. The company operates in a single segment of the streaming business.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.